Clinical Oncology: Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Therapy Development for Diffuse Large B-cell Lymphoma in its Limited Stage

The most prevalent Non-Hodgkin Lymphoma (NHL) is Diffuse Large B-Cell Lymphoma (DLBCL), with limited-stage DLBCL being classified as stage I or stage II illness. Advanced-stage DLBCL differs from early-stage DLBCL in risk classification, initial treatment options, and recurrence patterns, however there is little information on the influence of biologic characteristics on outcome. Patients achieve outstanding results, with a 2-year survival rate of almost 90%. Sequential prospective trials and sizable registry studies have assessed the ideal number of chemotherapy cycles and applied PET-adapted strategies to lessen the requirement for radiotherapy during the past few years. Bulky disease, extra nodal disease, totally resected situations, and unfavorable biologic characteristics including high-grade B-cell lymphoma with double/triple hit rearrangements still require special attention.

Special Features

Full Text


Track Your Manuscript

Media Partners